
https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Paragraphs discussing the issue of drug shortages during Covid-19]

[Signature]
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

CMA POLICY

Cannabis for Medical Purposes

Cannabis is a Schedule I controlled drug under the Federal Controlled Drugs and Substances Act. While the use of cannabis for medicinal purposes is still illegal in Canada, the Canadian Medical Association (CMA) recognizes that the growing body of evidence on the therapeutic effects of cannabis is compelling, and the potential benefits of cannabis to patients with debilitating conditions may outweigh the risks.

The CMA supports the following recommendations:

1. Increase access to the controlled use of cannabis for medical purposes. The CMA encourages the federal government to support clinical research, assess the risks and benefits, and develop guidelines for the safe and effective use of cannabis.

2. The CMA encourages a comprehensive regulation of cannabis, including strict controls on cultivation, manufacture, distribution, and use.

3. The CMA supports the regulation of the sale and distribution of cannabis to ensure public safety and health, and to prevent the diversion of cannabis to unauthorized users.

4. The CMA recommends that the federal government work with the provinces and territories to develop a comprehensive regulatory framework for the sale and distribution of cannabis.
Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  Response to consultation
DATE  2019-02-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA response:
HEALTH CANADA CONSULTATION ON EDIBLE CANNABIS, EXTRACTS & TOPICALS
February 20, 2019
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE
Response to consultation

DATE
2018-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-10-02</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety</td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

Documents

CMA submission:
IMPLEMENTATION OF NATIONAL PHARMACARE

Submission to the Advisory Council
November 2018
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE  Response to consultation
DATE  2018-09-06
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE  Policy endorsement

DATE  2018-08-30

TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE  
Response to consultation

DATE  
2018-08-14

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE Response to consultation
DATE 2018-07-18
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE  Response to consultation
DATE  2018-04-23
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear [Recipient],

The Canadian Medical Association (CMA) has been approached by Health Canada to contribute to the evaluation of the Front of Package (FOP) Labelling of Health Products Act. The Act proposes to require the labelling of some health products with a designated number of points of information concerning their health risks and benefits. This information is to be placed on the packaging of health products, in a designated location, that is clearly visible to consumers.

The CMA believes that public health experts have a role to play in ensuring that health products are labelled in a way that is both informative and accessible to consumers. The CMA is concerned that the proposed labelling system may be difficult for consumers to understand and may not provide sufficient information to make informed decisions about their health products.

The CMA recommends that the proposed labelling system be revised to ensure that it is clear and informative. The CMA also recommends that the labelling system be evaluated to ensure that it is effective in promoting public health.

Sincerely,

[Your Name]

Cc: [Other Names]

[Note: The above text is an example of how the consultation might be addressed. The actual text would depend on the specific details provided by Health Canada and the CMA's analysis of the proposed labelling system.]

Bill C-45: The Cannabis Act
CMA Policybase - Canadian Medical Association
p. 15
CMA's Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE
Response to consultation

DATE
2018-01-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE
Response to consultation

DATE
2017-12-07

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE
Response to consultation

DATE
2017-11-7

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescribers only.

November 7, 2017